Huang Xue-shan, Chen Dao-zhong, Chen Liang-wan, Lin Feng, Weng Qin-yong, Qiu Han-fan, Huang Zhong-yao, Liao Chong-xian
Department of Cardiac Surgery, Union Hospital, Fujian Medical University, Fuzhou 350001, China.
Zhonghua Yi Xue Za Zhi. 2005 May 11;85(17):1198-200.
To summarize the experience in donor-recipient gender mismatching heart transplantation.
Seven female patients with end-stage cardiopathy aged 13 approximately 44, underwent orthotopic transplantation of hearts from male donors. Fine-tuning immunosuppressive protocols were adopted: Stanford classic therapy was applied on 3 cases and immunosupression induction therapy was applied on 4 cases. The clinical outcomes were observed for an average of 20 months (5 approximately 54 months).
No acute reject reaction was found in all 7 cases within 3 months postoperatively. The earliest 2 patients died of refractory rejection 38 and 34 months postoperatively due to immunosuppressive withdrawal because of financial difficulty. The other 5 cases resumed their normal work and daily life. No allograft dysfunction, severe opportunistic infection episodes, and injury of liver and kidney functions were found in all cases.
Fine-tuning immunosuppressive protocols improve the short-term and long-term clinical effects of donor-recipient gender mismatching heart transplantation.
总结供受者性别不匹配心脏移植的经验。
7例终末期心脏病女性患者，年龄13至44岁，接受了男性供体心脏的原位移植。采用了微调免疫抑制方案：3例采用斯坦福经典疗法，4例采用免疫抑制诱导疗法。平均观察临床结果20个月（5至54个月）。
7例术后3个月内均未发生急性排斥反应。最早的2例患者因经济困难停用免疫抑制剂，分别于术后38个月和34个月死于难治性排斥反应。其他5例恢复了正常工作和日常生活。所有病例均未发现移植器官功能障碍、严重机会性感染发作以及肝肾功能损伤。
微调免疫抑制方案可改善供受者性别不匹配心脏移植的短期和长期临床效果。
